34 C
Vientiane
Tuesday, May 6, 2025
spot_img
Home Blog Page 350

Gynecomastia Affects All Ethnic Groups in Singapore, Amaris B. Clinic Study Reveals

Amaris B. Clinic releases insights into gynecomastia cases, proving the condition affects men of all races in Singapore.


SINGAPORE – Media OutReach Newswire – 25 March 2025 – Gynecomastia, the development of excess male breast tissue disorder, is far more common than reported, yet it remains a misunderstood medical condition that is surrounded by stigma and misconceptions. One of the biggest myths in Singapore is that this enlarged male breast condition affects a particular racial group more than other ethnic groups.

Ethnicity of gynecomastia patients at Amaris B. Clinic from January 2018 to December 2024
Ethnicity of gynecomastia patients at Amaris B. Clinic from January 2018 to December 2024

Gynecomastia Transcends Beyond Ethnicity
Dr Ivan Puah, Medical Director of Amaris B. Clinic and an MOH-accredited liposuction doctor in Singapore, has spent nearly two decades successfully treating men struggling with gynecomastia, helping them regain confidence through his proprietary gynecomastia surgical approach – 360° GTD technique.

His recent study, analysing 602 patients treated for gynecomastia between January 2018 and December 2024, proved that gynecomastia affects men of all ethnicities in Singapore — debunking stereotypes that single out one racial group.

Dr Ivan Puah emphasised, “There is a common belief in Singapore that gynecomastia is more prevalent in certain ethnic groups, but my experience tells a different truth. I’ve treated patients from all racial backgrounds, proving that this condition isn’t selective — it can happen to any man, regardless of ethnicity.”

The Importance of Proper Diagnosis & Surgery

Not all gynecomastia cases are the same. Some men develop true gynecomastia, which involves excess glandular tissue, while others have mixed gynecomastia, a combination of glandular and fatty tissue. A proper medical diagnosis is crucial in determining the best treatment approach.

Dr Puah’s 360° Glandular Tissue Dissection (360° GTD) technique is less invasive. Unlike traditional gynecomastia surgeries, his technique effectively eliminates glandular tissue while achieving a more sculpted and masculine chest with minimal downtime and well-concealed scarring.

Gynecomastia in Singapore: The Reality Behind the Numbers
The study identified the patient demographics of individuals who sought gynecomastia surgery from Dr Ivan Puah:

  • 42.6% (263 patients) were Chinese
  • 19.7% (117 patients) were Indian
  • 12% (71 patients) were Caucasian
  • 8.9% (53 patients) were Malay

The rising number of Chinese patients seeking gynecomastia surgery at Amaris B. Clinic reflects a growing awareness, not higher susceptibility. Factors such as hormonal imbalances, genetics, obesity, underlying medical conditions, use of anabolic steroids and taking certain types of medications can lead to the development of male breast enlargement in Singapore, not ethnicity.

Why Many Men Suffer in Silence
Gynecomastia can have a devastating impact on self-esteem, causing not only physical discomfort such as pain and breast swelling but also crippling men’s confidence. Despite being common and treatable, many suffer in silence due to shame, misinformation, or fear of judgment.

“Our study proves no ethnicity is immune, and timely care is critical. Gynecomastia is not just a Singaporean issue, but it also transcends ethnicity, affecting men of all races and backgrounds globally. Too often, men think they have to just ‘live with it’ or that this medical condition is something they should be embarrassed about,” Dr Puah shares. “That couldn’t be further from the truth. Seeking expert help is the first step toward a better well-being and reclaiming your confidence.”

For those experiencing symptoms, an in-depth consultation with an experienced doctor in treating gynecomastia is essential for proper diagnosis and personalised treatment. With advancements in surgical techniques and a better understanding of the condition, no man should have to live with gynecomastia in silence.
Hashtag: #AmarisB.Clinic





The issuer is solely responsible for the content of this announcement.

About Amaris B. Clinic & Dr Ivan Puah

Established in 2004, Amaris B. Clinic is a medical aesthetics, sculpting and fitness clinic in Singapore. Led by Dr Ivan Puah, who is the clinic’s Medical Director and accredited by the Ministry of Health to perform liposuction, Amaris B.’s forte lies in body sculpting – surgically removing stubborn fat pockets to sculpt and shape different areas of the body through various services offered.

Chairman of the Lipo Peer Review Committee in Singapore, Dr Puah obtained his Vaser liposuction (fundamental and hi-definition) training in Colorado and Argentina. He has also received training in syringe liposculpture, fat grafting and thread lift by renowned French plastic surgeon, Dr Pierre Francois Fournier, and dedicated surgical training in gynecomastia surgery in San Francisco.

Dr Puah holds a Graduate Diploma in Family Dermatology from NUS, a Graduate Diploma in Acupuncture from TCMB, and a Graduate Diploma in Sports Medicine from LKCMedicine, NTU. He is the appointed trainer by Allergan and Merz for fellow doctors on cosmetic injectables such as neurotoxins and dermal fillers, as well as the designated trainer for PDO thread lift and Picolaser from Venusys Medical in Singapore.

Amaris B. Clinic’s signature treatments include:

Notice to Long-term Integra Lifesciences Holdings Corporation (IART) Shareholders: Grabar Law Investigates Claims on Your Behalf

Philadelphia, Pennsylvania – Newsfile Corp. – March 24, 2025 – Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company.

Current Integra LifeSciences Holdings Corp. (NASDAQ: IART) shareholders who have held the stock since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them. Learn more or join at: https://grabarlaw.com/the-latest/intrga-lifesciences-shareholder-investigation/. Contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.

WHY: An underlying securities fraud class action complaint alleges that Integra, via certain of his officers and directors, repeatedly touted that it was on track to grow SurgiMend’s market by obtaining FDA approval for use in post-mastectomy reconstruction, yet on May 23, 2023, the Company was forced to announce a “recall” of all products manufactured at its Boston Facility between March 1, 2018 and May 22, 2023. Integra LifeSciences explained that it had determined that the Boston Facility deviated from good manufacturing practices in testing for bacterial endotoxin and allowed the release of products with unsafe levels of endotoxins. As a result of the recall and manufacturing shutdown, the Company revised its guidance for the second quarter of 2023, lowering its revenue expectations by and disclosed that it expected to take a $22 million impairment due to the inventory write-off.

WHAT TO DO NOW: Current Integra LifeSciences shareholders who have held Integra LifeSciences shares since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.

If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/intrga-lifesciences-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. $IART #IntegraLifeSciences

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com

The issuer is solely responsible for the content of this announcement.

MongoDB Expands Availability of MongoDB Atlas in Southeast Asia to Support Accelerated Regional Growth

MongoDB Atlas now available on AWS Regions in Malaysia and Thailand // Local availability empowers businesses across the region—including Botnoi and EasyEat—to innovate and improve user experiences


SINGAPORE – Media OutReach Newswire – 25 March 2025 – MongoDB, the leading database for modern applications, today announced that its industry-leading, multi-cloud data platform, MongoDB Atlas, is now available on Amazon Web Services (AWS) Regions in Malaysia and Thailand. This expansion comes on the heels of significant growth in the Southeast Asia region with headcount growing over 200% in the last two years and the region becoming a key part of MongoDB’s Asia Pacific business, which has reached more than $220 million USD in annual revenue.

Already available across cloud regions in Australia, Hong Kong, India, Indonesia, Japan, Singapore, and South Korea, MongoDB Atlas is fueling MongoDB’s growth across Southeast Asia. MongoDB Atlas provides tens of thousands of customers around the world the performance, resilience, security, and flexibility to build their modern applications. With MongoDB Atlas on AWS, Malaysian and Thai customers in the financial services, telecommunications, healthcare, agritech, and manufacturing sectors—such as Botnoi and EasyEat—can now enjoy ultra-high availability, data sovereignty, and lower latency.

“Bringing MongoDB Atlas to Malaysia and Thailand on AWS is a big milestone for us, and is an important step in MongoDB’s growth across the region,” said Stewart Garrett, Regional Vice President, ASEAN and Japan, MongoDB. “We’re giving businesses the tools to tap into real-time insights, strong security, and unmatched scalability so they can roll out modern applications faster. This launch goes beyond improved availability and latency—it supports digital transformation, sparking innovation and boosting economic growth across Southeast Asia.”

“AWS is committed to helping customers innovate with the best tools and technologies where they need them most,” said Kirsten Gilbertson, Partner Organization Leader, ASEAN, AWS. “We’re excited to support MongoDB Atlas’s expansion into Malaysia and Thailand, bringing powerful database capabilities closer to customers on our regional infrastructure. This collaboration helps businesses across Southeast Asia innovate faster while meeting their data residency requirements and performance needs.”

Customers welcome MongoDB Atlas regional expansion

MongoDB customers across Southeast Asia are seeing rapid innovation and growth with MongoDB Atlas.

Thailand’s Botnoi is using MongoDB Atlas to efficiently manage and analyze large datasets, which is essential for providing AI applications like chatbots and voice bots to automate customer service and technical support. “MongoDB Atlas on AWS helps us manage and analyze huge volumes of data easily, allowing us to rapidly innovate to deliver improved customer service solutions for our clients,” said Dr. Piyoros Tungthamthiti, Chief Technology Officer and Co-Founder of Botnoi. “We are thrilled that MongoDB is expanding Atlas to our country, allowing us to benefit from the scalability and agility of the cloud infrastructure right here in Bangkok.”

Malaysia’s EasyEat delivers a software-as-a-service point-of-sale system to restaurants. With MongoDB Atlas, the company simplifies daily operations, optimizes costs, and enhances customer satisfaction for more than 2,000 restaurants and over four million consumers across Malaysia and Indonesia. “Our customers depend on us to manage their data to improve the customer experience. With MongoDB Atlas now hosted locally in Malaysia, we can accelerate our innovation efforts,” said Abdul Khalid, Co-Founder & CTO, EasyEat. “We expect that with MongoDB we will further simplify our operations, costs, and user satisfaction while keeping our data in-country.”
Hashtag: #MongoDB


The issuer is solely responsible for the content of this announcement.

About MongoDB

Headquartered in New York, MongoDB’s mission is to empower innovators to create, transform, and disrupt industries with software and data. MongoDB’s unified, intelligent data platform was built to power the next generation of applications, and MongoDB is the most widely available, globally distributed database on the market. With integrated capabilities for operational data, search, real-time analytics, and AI-powered retrieval, MongoDB helps organizations everywhere move faster, innovate more efficiently, and simplify complex architectures. Millions of developers and more than 50,000 customers across almost every industry—including 70% of the Fortune 100—rely on MongoDB for their most important applications. To learn more, visit .

Jian’ge County in Guangyuan Hosts Handover Ceremony for Over 12,000 Ancient and Famous Trees


GUANGYUAN, CHINA – Media OutReach Newswire – 24 March 2025 – On March 12, marking the 47th Arbor Day of China, the “Shu Road Cuiyun Corridor Ancient Cypress Conservation Handover Ceremony” was held in Jian’ge County, Guangyuan City, Sichuan Province. More than a hundred town and township cadres, forest rangers and villagers witnessed this special handover event, who gathered to witness the transfer of responsibility for the stewardship of more than 12,000 ancient and famous trees. Among these venerable beings, the eldest boasts an impressive age of approximately 2,300 years.

On March 15, Hope Justman (middle) and her friends strolling on the ancient Shu Road in Jiange County, Guangyuan City. Photo by Liu Ren
On March 15, Hope Justman (middle) and her friends strolling on the ancient Shu Road in Jiange County, Guangyuan City. Photo by Liu Ren

Since the Ming Dynasty, Jian’ge County has upheld a tradition of conducting handover ceremonies for ancient cypresses along its trade routes during the transition between incoming and outgoing officials. As part of this practice, the officials meticulously count the number of ancient cypresses and record their survival and growth conditions in the area. To this day, the handover of ancient and famous trees remains a vital aspect of transfer of duty in Jian’ge County, symbolizing the enduring commitment to safeguarding these venerable trees across generations.

Located in the northern part of Sichuan, Jian’ge County stands as a pivotal landmark along the ancient, a trade route boasting a history of more than 2,000 years. Renowned for its wealth of transportation relics and cultural landscapes that bear witness to the passage of time, it has earned the title of “a living fossil of ancient land transportation”.

As early as 2015, the ancient Shu Road was already added to the UNESCO World Heritage Tentative List, and has since been nominated as a candidate for both World Natural and Cultural Heritage status.

Within the ancient Shu Road, a stretch of nearly 300 kilometers lies in Guangyuan City, Sichuan Province, renowned as the section with the most abundant relics and historical narratives. Particularly notable is the Cuiyun Corridor in Jian’ge County, which boasts the world’s largest, oldest, and most extensive cluster of ancient trees planted along an historic route. Currently, a total of 7,803 ancient trees remain, including 7,778 ancient cypresses with an average age of 1,050 years. The verdant trees block out sunlight, creating an ethereal atmosphere that makes walking beneath them feel like stepping into a living painting.

In recent years, the ancient Shu Road has gradually emerged as a sought-after destination among both Chinese and foreign tourists thanks to its unique charms. On March 13, 82-year-old American explorer Hope Justman, accompanied by her friends, explored iconic sites such as Jianmen Pass and the Cuiyun Corridor, immersing themselves in the rich culture of the Shu Road and the timeless grandeur of its ancient trees. This marked her 25th journey along this millennia-old historic route.

To better protect the ancient and famous trees, local authorities perform “physical check-up” for them on a regular basis, including inspections for hollowing and decay, cleaning and treating damaged areas of trunks, and performing “minimally invasive surgeries”. Over the past three years, Jian’ge County has successfully restored and rescued 2,478 endangered and weakened ancient cypresses.

On March 15, China officially enacted the Regulations on the Protection of Ancient and Famous Trees, marking the first time the country has established standardized management and protection practices for these trees through administrative legislation. Notably, the Regulations drew inspiration from the ancient cypress handover system of the Cuiyun Corridor along the historic Shu Road.

Cuiyun Corridor on the ancient Shu Road. Photo by Meng Libo
Cuiyun Corridor on the ancient Shu Road. Photo by Meng Libo

Hashtag: #JiangeCounty

The issuer is solely responsible for the content of this announcement.

Exceptional Partnership: Princess Madeleine and Weleda Launch New Skincare Brand, minLen

  • The first natural, responsible multi-generational skincare brand in Europe
  • Princess Madeleine: “Weleda is the ideal partner for developing products that nurture and protect children’s natural skin barrier. As a mother, I am mindful about the skincare products my family uses, making minLen a deeply personal project for me.”
  • Weleda CEO Tina Müller: “At a time when even young children are reaching for their mother’s retinol cream, we are introducing an alternative the whole family can use without hesitation. We are honoured to have realised this important project with Madeleine.”
  • First joint public appearance: 28 March 2025, Düsseldorf

ARLESHEIM, STOCKHOLM – Newsaktuell – 24 March 2025 – Weleda AG, the global leader in certified natural skincare and anthroposophic medicines, has partnered with Princess Madeleine – under her private name, Madeleine Bernadotte – to co-develop minLen, a new natural skincare brand. This marks her entry into the beauty industry as an entrepreneur.

Exceptional Partnership: Princess Madeleine and Weleda Launch New Skincare Brand, minLen. Left: Weleda CEO Tina Müller, Right: Princess Madeleine, Credit: Henning Ross
Exceptional Partnership: Princess Madeleine and Weleda Launch New Skincare Brand, minLen. Left: Weleda CEO Tina Müller, Right: Princess Madeleine, Credit: Henning Ross

Through their collaboration, Madeleine Bernadotte and Weleda address a concerning social trend: children and young people are increasingly using skincare products with active ingredients unsuitable for their age. “As parents, we have a responsibility to help our children make mindful choices about skincare products,” says Madeleine Bernadotte. “I felt there was a need for a product line that not only prioritises safety but is also fun to use – made with natural ingredients, beautifully scented, and thoughtfully designed with appealing packaging for the whole family.”

LogominLen

The science-backed, family-friendly minLen skincare range offers exceptionally gentle, high-quality skincare, specially formulated for babies, children, and young adults. Made with natural ingredients and meeting the highest quality standards, the range has been created in close collaboration with leading experts in dermatology and natural medicine. As a mother of three, Madeleine Bernadotte understands the importance of using products specifically designed for children: “Children’s skin is delicate and requires the utmost care. That’s why Weleda is the perfect partner to create products that gently protect and strengthen their natural skin barrier.”

Tina Müller, CEO of Weleda, is thrilled about this exceptional partnership: “We are excited to have developed this new skincare line with someone as dedicated as Princess Madeleine. Her passion for this topic and her entrepreneurial spirit has inspired us from the start. The range aligns perfectly with Weleda’s primary mission: providing gentle, effective, and certified natural skincare that people around the world trust.”

Müller highlights the significance of this new joint brand as an age-appropriate alternative: “Inspired by social media, children and young people today increasingly use products that are completely unsuitable for their age, containing retinol and acids. minLen has the potential to set a new trend: 100% natural skincare that provides exceptionally gentle care and reliable protection, while redefining the fun of skincare. We combine the latest scientific insights with the power of nature to create high-quality care products for the whole family.” The minLen range harnesses the natural benefits of flax flower, wild blueberry, and sea buckthorn, known for their skin-nurturing properties.

Madeleine Bernadotte and Weleda have been working intensively on this new product family since January 2024. The brand name minLen is derived from Swedish and combines “my” (min) with “soft” (len). Len is also Princess Madeleine’s nickname.

minLen will be available from September 2025, initially in Germany, Austria, Switzerland, and Sweden – additional markets will follow. Targeted distribution will take place through Weleda web shops, perfumeries, flagship department stores, selected e-commerce platforms, and pharmacies in Sweden. The minLen product range – including face cream, shampoo & body wash, body lotion, lip balm, and body oil – will retail between approximately €10 and €30, with sunscreen products to be introduced for the 2026 season.

As part of the “The Art of Beauty & Health” summit, Madeleine Bernadotte and Weleda will officially launch their new brand minLen with a public presentation and a press conference on 28 March in Düsseldorf.Hashtag: #Weleda

The issuer is solely responsible for the content of this announcement.

About Weleda

Weleda AG is a Swiss public limited company with its headquarters in Arlesheim near Basel. Weleda is represented in over 50 countries and employs around 2,500 people. Weleda is the world’s leading manufacturer of certified natural cosmetics and anthroposophic pharmaceuticals. Weleda runs six gardens of its own using biodynamic cultivation methods and is particularly committed to biodiversity and healthy soils. Weleda is a certified B Corp.

More information about the Weleda Group can be found at

Please note that we will address questions regarding the collaboration only during the press conference on 28 March 2025.

Cathay expands lifestyle offerings in Southeast Asia with Mitsui Mall Group partnership in Malaysia


KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 24 March 2025 – Premium travel lifestyle brand Cathay is strengthening its lifestyle presence in Southeast Asia through an exciting new partnership with Mitsui Mall Group in Kuala Lumpur. This collaboration opens up new ways for Cathay members to earn Asia Miles while shopping or dining at two popular retail hubs in Kuala Lumpur—Mitsui Outlet Park KLIA Sepang and Mitsui Shopping Park LaLaport BBCC.

Cathay expands lifestyle offerings in Southeast Asia with Mitsui Mall Group partnership in Malaysia

An elevated shopping experience with Asia Miles and limited-time rewards
Effective immediately, Cathay members can earn 1 Asia Mile for every RM5 spent at both malls and enjoy exclusive mall privileges to elevate their shopping experience. Miles earned can be used to redeem flights with over 20 airline partners, more than 10,000 lifestyle products on Cathay Shop, and exclusive rewards and experiences with any of Cathay’s 800 travel and lifestyle partners worldwide.

To celebrate this partnership, Cathay members can enjoy double miles (2 Asia Miles for every RM5 spent) on all eligible spending from now until 31 May 2025. Additionally, new Cathay members can earn up to 1,000 Asia Miles—they will receive 300 bonus miles upon sign-up, and additional 700 miles after their first transaction.

Exclusive mall privileges

In addition to boosting their miles, Cathay members can unlock exclusive privileges at both malls.

At Mitsui Shopping Park LaLaport BBCC, all Cathay members can access the Tourist Privilege Card, unlocking instant discounts, special offers, and exclusive rewards by presenting their Cathay membership at the Ground Floor information counter. Members who spend a minimum of RM300[1] will receive an exclusive luggage tag as a special gift.

At Mitsui Outlet Park KLIA Sepang, Cathay members visiting Kuala Lumpur can register for a free Tourist Privilege Pass to enjoy additional discounts and privileges by presenting their passports at the information counter.

Cathay Regional General Manager for Southeast Asia Dominic Perret said, “At Cathay, we strive to seamlessly blend travel and lifestyle so that our members can earn miles through a variety of everyday activities, bringing them closer to their next flight, exclusive experience, or lifestyle reward. We are therefore delighted to partner with Mitsui Mall Group to offer our members even more ways to earn and redeem Asia Miles in Kuala Lumpur. In Southeast Asia, this marks another addition to our list of popular shopping malls where our members can earn rewards and enjoy exclusive privileges, alongside our existing partnership with Siam Piwat Group in Thailand.”

For more details, please visit Cathay’s website.

Cathay’s expanding shopping partner network

This collaboration further strengthens Cathay’s lifestyle ecosystem, allowing members to earn and redeem rewards beyond travel. Mitsui Shopping Park LaLaport BBCC and Mitsui Outlet Park KLIA Sepang in Kuala Lumpur join Cathay’s lineup of other retail partners around the world, including:

  • Mitsui Outlet Park Taiwan (Taiwan, China)
  • Mitsui Shopping Park LaLaport Taichung (Taiwan, China)
  • Mitsui Outlet Park (Japan)
  • Lotte Duty Free Ginza (Japan)
  • Siam Piwat Group (Thailand)
  • Shinsegae Duty Free (South Korea)
  • The Bicester Collection (Europe and China)

With this growing network, Cathay members can seamlessly turn their shopping experiences into rewarding journeys.

Beyond flights, Cathay’s travel lifestyle offerings consist of a host of complementary categories—holidays, shopping, dining, wellness and payment, designed to bring customers exciting offers, rewards, and experiences with hand-picked partners. Discover the Cathay lifestyle here.


[1] Terms and conditions apply.

Hashtag: #Cathay

The issuer is solely responsible for the content of this announcement.

Gorilla Technology Dismisses Misinformation, Confirms Intention to Acquire Shares by Company and Insiders


London, United Kingdom – Newsfile Corp. – 24 March 2025 – Gorilla Technology Group Inc. (NASDAQ: GRRR) (“Gorilla” or the “Company”) issued a press statement.

“Gorilla Technology will not engage with baseless allegations spread by individuals charged by multiple authorities with fraud and market manipulation. Given the multiple charges filed by both the U.S. Securities and Exchange Commission (SEC) and the U.S. Department of Justice (DOJ) against those behind these claims, their credibility is highly questionable. Our legal counsels across multiple jurisdictions are currently engaged in this matter. We will let our results and our business strategy speak for themselves,” said Jay Chandan, Chairman & CEO of Gorilla Technology.

Given the fall in the Company’s share price in connection with recent short selling, Gorilla’s Board of Directors once again believes the shares to be deeply undervalued. Therefore, the Company will utilize funds remaining under its previously announced share buyback programme following the release of its 2024 earnings statement if the share price continues to fail to reflect what the Board sees as the Company’s intrinsic value.

In addition, it is the intent of a large portion of the Board and the entire executive management team to acquire shares following the Company’s earnings release. Jay Chandan added, “We believe in this company, in our vision and in the undeniable momentum we have built. The market will eventually catch up and we are putting our money where our conviction is.”

About Gorilla Technology Group Inc.

Headquartered in London U.K., Gorilla is a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology. We provide a wide range of solutions, including Smart City, Network, Video, Security Convergence and IoT, across select verticals of Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare and Education, by using AI and Deep Learning Technologies.

Our expertise lies in revolutionizing urban operations, bolstering security and enhancing resilience. We deliver pioneering products that harness the power of AI in intelligent video surveillance, facial recognition, license plate recognition, edge computing, post-event analytics and advanced cybersecurity technologies. By integrating these AI-driven technologies, we empower Smart Cities to enhance efficiency, safety and cybersecurity measures, ultimately improving the quality of life for residents.

For more information, please visit our website: Gorilla-Technology.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Gorilla’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, statements regarding our beliefs about the Company’s intrinsic value and the ability of its board members and management team to purchase shares in the open market, along with those other risks described under the heading “Risk Factors” in the Form 20-F Gorilla filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2024 and those that are included in any of Gorilla’s future filings with the SEC. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside of the control of Gorilla and are difficult to predict. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Gorilla undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.

Contact:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
GRRR@redchip.com

The issuer is solely responsible for the content of this announcement.

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist


GUANGDONG, CHINA AND BAGSVÆRD, DENMARK – Media OutReach Newswire – 24 March 2025 – The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.

Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251. United Biotechnology will retain the rights for UBT251 in Chinese mainland, Hong Kong, Macau, and Taiwan. United Biotechnology is eligible to receive an upfront payment of 200 million US dollars and potential milestone payments of up to 1.8 billion dollars from Novo Nordisk, as well as tiered royalties on net sales outside of Chinese mainland, Hong Kong, Macau, and Taiwan.

“Novo Nordisk is dedicated to providing improved treatment options for people living with obesity, type 2 diabetes, and other cardiometabolic diseases. The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment options that cater to the diverse needs of people living with these highly prevalent diseases,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk. “We look forward to building on United Biotechnology’s scientific work and further exploring the potential best-in-class properties of UBT251 across cardiometabolic disease indications.”

United Biotechnology recently completed a randomized, double-blind, placebo-controlled phase 1b trial in China designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple subcutaneous injections of UBT251 in people with overweight or obesity.

A total of 36 patients were enrolled in three different dose groups (1mg, 1mg/3mg, 1mg/3mg/6mg). Each group adopted a dose titration method, with subcutaneous injection once a week for 12 consecutive weeks.

The safety profile of UBT251 was consistent with incretin-based therapies. The most common adverse events were gastrointestinal and the vast majority were mild to moderate in severity. In the highest dose group, the average weight of the people who completed the trial decreased by 15.1% from baseline, while the average weight of people in the placebo group increased by 1.5% from baseline.

“We are pleased to announce our exclusive license agreement with Novo Nordisk for UBT251. As a leading global biopharmaceutical company, Novo Nordisk holds a strong position in the treatment of chronic diseases,” said Mr. Tsoi Hoi Shan, the Chairman of TUL. “TUL is committed to strengthening its presence in the treatment of chronic diseases, including endocrine and metabolic disorders, while actively expanding its footprint in global markets. We believe that Novo Nordisk’s expertise will play a key role in accelerating the global development of UBT251.”

This collaboration represents a pivotal milestone in TUL’s ongoing efforts to establish a global strategic presence and demonstrates its commitment to innovation-driven transformation. TUL will continue to foster scientific innovation, advance high-quality and sustainable development, and accelerate the establishment of a globally competitive framework for manufacturing, R&D, and commercialization.

The closing of this transaction is subject to applicable regulatory clearance and other customary closing conditions.
Hashtag: #TUL

The issuer is solely responsible for the content of this announcement.

About UBT251

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has demonstrated potent activity on all three receptors in a preclinical setting.

UBT251 is categorized as a Class 1 innovative drug in China, being developed by United Biotechnology for multiple indications. To date, UBT251 has been approved for clinical trials in China in adult type 2 diabetes, overweight or obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), and chronic kidney disease (CKD), and for clinical trials in the United States in adult type 2 diabetes, overweight or obesity, and CKD.

United Biotechnology recently initiated a phase 2 trial for UBT251 in people with overweight or obesity in China.

About TUL and United Biotechnology

Founded in 1990, TUL (HKEX: 3933) is mainly engaged in the research and development, production and sales of pharmaceuticals, and ranks among the leading integrated pharmaceutical companies in China. TUL currently boasts seven production bases, covering intermediate products, bulk medicine , finished products, veterinary drugs, empty capsule casings, and medical devices, with the sales networks dotted across nearly 80 countries and regions. United Biotechnology, located in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, serves as the biopharmaceutical R&D headquarter of TUL. United Biotechnology focuses on the development of high-end biopharmaceuticals to treat major chronic diseases. For more information, please visit .

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit , , , and .